BioSpace News Archive

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Tuesday, January 14, 2020 at 11:00am (PT) at Hilton San Francisco Union Square.

SpendEdge has been monitoring the global culture media market and the market is poised to experience spend growth of more than USD 3 billion between 2019-2024 at a CAGR of over 8% during the forecast period.

Technavio has announced its latest market research report titled global cryogenic vials market 2020-2024

Progentec, a leader in the development of nextgen diagnostics and digital therapeutics for the management of autoimmune diseases, announced today that it has completed a $5 million Series A funding round led by Plains Venture Partners, the Oklahoma Seed Capital Fund and the Oklahoma Angel Capital Fund II, managed by i2E Management Company (Oklahoma City),

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, is scheduled to present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference

Minnesota dentists are offering free dental care to children in need on February 7 and 8, 2020.

Jennewein Biotechnology announces another milestone in the worldwide approval of a new product generation, the “HMO-Mix.”

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced a publication that demonstrates how Cellvizio positively impacts the diagnostic yield and the clinical management of pancreatic cystic lesions (PCL)

Phillips-Medisize, a Molex company, announced expansion of its current Global Innovation and Development site in Struer, Denmark with a dedicated Manufacturing Development and Clinical build unit, which is scheduled to open in the second quarter of 2020.

American Cancer Society’s (ACS) Cancer Facts & Figures report, released today, states that the five-year survival rate for pancreatic cancer has increased from 9 to 10%, according to the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER)-9 database.